Physician profile
John Alvarez
NPI 1255692083
$12,062.74
in general payments reported to CMS, 2019-2025
41 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $872 · 2021: $2,246 · 2022: $2,300 · 2023: $1,859 · 2024: $1,899 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,028 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.46 |
| Education | $186.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,431.17 | 2019-2025 | Exalt Model D, Habib Endohpb, Axios |
| Abbvie INC. | $2,561.19 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Olympus America INC. | $1,253.37 | 2020-2023 | Hanarostent Lowaxtm Duodenum/Pylorus(Nnn) |
| Janssen Biotech, INC. | $981.85 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.94 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $363.71 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $331.57 | 2024-2025 | Voquezna |
| Pfizer INC. | $289.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $231.09 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $159.08 | 2021 | |
| Lilly USA, LLC | $157.30 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $153.50 | 2019-2025 | Eohilia |
| Ipsen Biopharmaceuticals, INC | $133.07 | 2024-2025 | Iqirvo |
| Olympus Corporation of The Americas | $128.42 | 2021-2022 | |
| Redhill Biopharma INC. | $126.24 | 2021-2025 | Talicia |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,506.37 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.